Brent Vaughan, CEO and Co-Founder, Eratos
Brent is CEO and co-founder of Eratos Therapeutics along with leading MIT neuroscientist, Edward Boyden, PhD (Y. Eva Tan Professor in Neurotechnology at MIT, Howard Hughes Medical Institute, McGovern Institute & Yang Tan Collective, MIT). Eratos Therapeutics is leveraging the groundbreaking scientific advances of Ed Boyden’s work and building a novel generative AI with deep, proprietary, domain-specific understanding of neurobiology and structure-function relationships throughout the brain that is enabling rapid identification of new targets and the more predictive development of CNS therapeutics.
Prior to founding Eratos, Brent founded and successfully scaled multiple companies and led the development of novel drug and medical device products from inception, creation of foundational IP, IND-enabling and product development through completion of multiple successful clinical programs that resulted in 3 FDA Breakthrough designations, FDA approval of the first-in-category ML/AI based CNS diagnostic and, one of the leading Alzheimer’s Ph3/pivotal development programs.
